Broncho-Vaxom Adult, capsules 7 mg, 30 pcs.

When taken orally, Broncho-Vaxom stimulates the body’s immune defense and increases resistance to infections of the respiratory system.

Immunopharmacological studies have shown that Broncho-Vaxom shows the following effects: in humans Broncho-Vaxom: increases the formation of immunoglobulin A secreted by respiratory tract mucosa and saliva, increases the number of circulating T-lymphocytes.

In animals, Broncho-Vaxom: actively protects against infections, stimulates B-lymphocytes and macrophages. Clinically Broncho-Vaxom reduces the frequency of acute infections, reduces the duration of their course and reduces the severity of symptoms, and reduces the likelihood of exacerbations of chronic diseases.

The need for other medications, especially antibiotics, is reduced.

Indications

Prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis.

Use in the complex treatment of acute respiratory tract infections.

Pharmacological effect

When taken orally, Broncho-Vaxom stimulates the body’s immune defense and increases resistance to infections of the respiratory system.

Immunopharmacological studies have shown that Broncho-Vaxom exhibits the following effects: in humans, Broncho-Vaxom: increases the formation of immunoglobulins A secreted by the mucous membrane of the respiratory tract and saliva, increases the number of circulating T-lymphocytes.

In animals, Broncho-Vaxom: actively protects against infections, stimulates B-lymphocytes and macrophages. Clinically, Broncho-Vaxom reduces the frequency of acute infections, shortens the duration of their course and reduces the severity of symptoms, and also reduces the likelihood of exacerbations of chronic diseases.

This reduces the need to use other medications, especially antibiotics.

Special instructions

No precautions are required when using the drug.

Impact on the ability to drive vehicles and operate machinery

Broncho-Vaxom® for adults does not affect the ability to drive vehicles or operate machinery.

Active ingredient

Bacterial lysates

Composition

1 caps.
standardized lyophilisate of bacterial lysates:
Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis
7 mg

Excipients:

propyl gallate anhydrous (E310) – 0.084 mg,

monosodium glutamate (corresponds to anhydrous sodium glutamate (sodium glutamate)) – 3.03 mg,

mannitol – required amount up to 40 mg,

pregelatinized starch – 110 mg,

magnesium stearate – 3 mg,

mannitol – required amount up to 200 mg.

Composition of the capsule shell:

indigo carmine (indigotine) (dye E132) – 0.03 mg, titanium dioxide (dye E171) – 1 mg, gelatin – required amount up to 50 mg.

Pregnancy

The use of Broncho-Vaxom® for adults during pregnancy and lactation is possible when the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Clinical studies of the drug in pregnant women have not been conducted.

No special studies have been conducted regarding the safety of use of the drug during breastfeeding; currently there is no data available.

Experimental studies on animals did not reveal any negative effects on the course of pregnancy, embryonic, fetal development and/or postnatal development.

Contraindications

Hypersensitivity to the components of the drug.

Based on available information, it is not recommended for use in children under 6 months of age due to the immaturity of their immune system.

To avoid overdose, children should not use the drug from capsules intended for adults.

Side Effects

Broncho-Vaxom® for adults is usually well tolerated. The results of clinical studies indicate that the frequency of mild adverse reactions is 3-4%.

From the digestive system: nausea, abdominal pain, vomiting.

Dermatological reactions: itching, erythema.

From the respiratory system: cough, shortness of breath.

From the nervous system: headache, feeling of fatigue.

In case of ongoing gastrointestinal disorders, skin reactions and respiratory manifestations, you should stop taking the drug, as they may be allergic reactions. In such a situation, the patient should consult with the attending physician.

Interaction

Broncho-Vaxom® adult can be used simultaneously with other medications for the treatment of acute and chronic respiratory diseases.

The interaction of the drug Broncho-Vaxom® adult with other drugs has not yet been established.

Overdose

There are no data on cases of overdose.

The nature of the drug Broncho-Vaxom® adult and the results of studies of its toxicity indicate that an overdose is unlikely.

Storage conditions

At 15–25 °C

Shelf life

5 years

Manufacturer

OM Pharma, Switzerland